Navigation Links
ANA380 Exhibits Activity In Vitro Against Multiple Clinically,Relevant Hepatitis B Virus Mutants

Poster Presentation at EASL on April 13, 2007, 2007

SAN DIEGO, and SEOUL, South Korea, April 13 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. and LG Life Sciences, Ltd., presented data from an in vitro study showing that ANA380 (LB80380) retains potency against multiple mutant strains of hepatitis B virus (HBV) which are resistant to lamivudine, adefovir, entecavir or telbivudine, during a poster presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, today at 1:00 p.m. CEST (7:00 a.m. EDT).

The study found that the in vitro antiviral potency of ANA380 against seven of nine mutants that were resistant to lamivudine, adefovir, entecavir or telbivudine was not significantly different from the antiviral potency against wild type HBV, indicated by a less than or equal to 2-fold difference in EC50, a measure of inhibition of virus replication. In addition, two HBV mutants that have been associated with clinical failure to entecavir or telbivudine, respectively, showed only small decreases (5 and 7 fold, respectively) in sensitivity to ANA380's antiviral effects in vitro. ANA380 was active against the HBV mutant resistant to telbivudine in prior clinical studies.

"This study illustrates the promising spectrum of antiviral activity for ANA380 against a defined panel of genetically defined drug-resistant HBV variants," said Dr. Stephen Locarnini, M.D., Ph.D., Head, Research & Molecular Development of the Victorian Infectious Diseases Research Laboratory in Melbourne, Australia.

"This study also suggests that ANA380/LB80380 may have clinical utility not only in drug-naïve patients but also in patients who have become resistant to the most commonly used HBV therapeutic agents," said Lawrence C. Fritz, Ph.D., president and chief executive officer of Anadys Pharmaceuticals. "Based on these data, we believe that
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
3. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
7. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/18/2013)... NEW YORK , May 18, 2013 /PRNewswire/ ... securities law firm, is investigating potential securities fraud ... (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ... the Company and its executives violated federal securities ... regarding the Company,s Phase III drug trials for ...
(Date:5/17/2013)... 2013 Medical devices are any medical items ... In light of their different mechanisms, actions and regulatory ... complicated than drug trails due to their unique clinical ... of evaluating both safety and efficacy (which is left ... the same as the SFDA) evaluate MDs for both ...
(Date:5/17/2013)...  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or STI) ... Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) from ... (NIAID), a division of the National Institutes of ... antibody therapeutics to combat Staphylococcus aureus ... methicillin-resistant S. aureus (MRSA), was renewed ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Statistical Challenges in Medical Device Trail Evaluation 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4
... indicates that anti-inflammatory drugs may become a new tool ... leading global cause of death. In investigating a specific ... researchers used the Cardiochip, a gene analysis tool designed ... Center for Applied Genomics at The Children,s Hospital of ...
... March 14, 2012 OncoSec Medical Incorporated ... Medical System (OMS) ElectroOncology therapies to treat solid ... Institute in Santa Monica, CA, and Lakeland Comprehensive ... as enrolling sites, and investigators are screening patients ...
Cached Medicine Technology:Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 2Gene Chip, Invented by Children's Hospital of Philadelphia Scientist, Pinpoints New Target to Prevent Heart Disease 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4
(Date:5/19/2013)... May 19, 2013 The report “Feed ... Trends & Forecasts up to 2017” published by MarketsandMarkets, ... with analysis and forecasting of the global volume and ... the driving and restraining factors for the global market ... and challenges. The market is segmented and revenue is ...
(Date:5/19/2013)... 19, 2013 Farming methods have changed ... the ground 10,000 years ago. Most recently, the Green ... by using genetically engineered seeds and by applying chemical ... backlash to these techniques due to the adverse environmental ... a corresponding surge in interest in organic, sustainable farming ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Yeast infections are ... appear in sensitive areas of the human body. A new ... This new formula provides a unique method of application to ... spray solution is now provided to men and women searching ... naturally absorbed in the body through food and is stored ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Beginning Wednesday, May ... Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" and ... RRVBC will provide hot dogs and all the fixin's ... slushies each day throughout the summer. “Donors are our lifeline. ... a stable and adequate blood supply. This is a ...
(Date:5/19/2013)... Minor fender benders and serious car ... parties to the accident to respond appropriately to the ... Prevention (CDC) data from 2010, accidents, including car accidents, ... In fact, in 2005, automobile accident-related deaths ... than 2.3 million drivers and passengers receive treatment in ...
Breaking Medicine News(10 mins):Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2
... ... superior performance in cell culture and addresses the need for animal-free transferrin in many ... , ... CO (PRWEB) September 16, 2009 -- InVitria today announced the launch of Optiferrin ...
... Hoffa Denounces 35 Percent Excise Tax on Higher-Cost Plans , ... said the proposal to impose a 35 percent tax on insurers for individual ... , , The proposal, introduced by Senate Finance Committee Chairman ... $21,000. , , "We,re pleased that Sen. Baucus stopped ...
... , , MINNEAPOLIS, Sept. ... announced the first ever meeting of thought leading spine surgeons to ... SI Joint pathology, a frequent cause of low back pain. ... included Steven Garfin (former president of NASS, Chief of Orthopedics at ...
... WASHINGTON, Sept. 16 Today U.S. Sen. Max Baucus (D-MT) ... of 2009" that will be marked-up in the Senate Financial ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , The ... that cover all elective abortions and moves well beyond the ...
... them directly related to success, study shows , WEDNESDAY, Sept. ... suspect they are in the middle of cardiac arrest, push ... more pushes, the better. , That,s the message of a ... related to the amount of time spent doing chest compressions ...
... NEW YORK, Sept. 16 As fall approaches, many women ... skinny jeans has you feeling uneasy, think again. Here,s more ... jeans. , , Listen to this report from ... Registered journalists can access video, audio, text, graphics and photos ...
Cached Medicine News:Health News:InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture 2Health News:Teamsters Oppose Baucus Plan to Tax Health Insurance Companies 2Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 2Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 3Health News:Academic Opinion Leaders in the Field of Spine Surgery & Sacroiliac Joint Experts Attend SI-BONE's National Summit on the Diagnosis of Sacroiliac Pathology 4Health News:Family Research Council: Senator Baucus Undermines President Obama's Abortion Funding Claim 2Health News:More Chest Compressions During CPR Improves Survival Odds 2
... Xtra™, and Maximum ACT™ introducers ... standard and specialty hemostasis introducers ... recognized as the premier hemostasis ... cardiology and electrophysiology procedures including ...
Lumenis 950 Slit Lamp Zeiss-style diagnostic slit lamp biomicroscope with parallel optics and offering a choice of automatic or fixed eye safety filters for multiple wavelengths....
... Adding the S-Link LaserLink to ... Selecta Duo, a versatile Nd:YAG ... laser that extends treatment capabilities ... anterior segment and posterior pole ...
... The Apeel CS Catheter Delivery System ... used for the placement of permanent ... Apeel CS Catheter Delivery System is ... torqueability, flexibility, and softness, plus high ...
Medicine Products: